Transcriptome, Spliceosome and Editome Expression Patterns of The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
And SPP-Like Proteases☆
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1828 (2013) 2828–2839 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamem Review Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases☆ Matthias Voss a, Bernd Schröder c, Regina Fluhrer a,b,⁎ a Adolf Butenandt Institute for Biochemistry, Ludwig-Maximilians University Munich, Schillerstr. 44, 80336 Munich, Germany b DZNE — German Center for Neurodegenerative Diseases, Munich, Schillerstr. 44, 80336 Munich, Germany c Biochemical Institute, Christian-Albrechts-University Kiel, Olshausenstrasse 40, 24118 Kiel, Germany article info abstract Article history: Signal peptide peptidase (SPP) and the homologous SPP-like (SPPL) proteases SPPL2a, SPPL2b, SPPL2c and Received 27 December 2012 SPPL3 belong to the family of GxGD intramembrane proteases. SPP/SPPLs selectively cleave transmembrane Received in revised form 25 March 2013 domains in type II orientation and do not require additional co-factors for proteolytic activity. Orthologues of Accepted 29 March 2013 SPP and SPPLs have been identified in other vertebrates, plants, and eukaryotes. In line with their diverse subcellular localisations ranging from the ER (SPP, SPPL2c), the Golgi (SPPL3), the plasma membrane Keywords: (SPPL2b) to lysosomes/late endosomes (SPPL2a), the different members of the SPP/SPPL family seem to Regulated intramembrane proteolysis fi Intramembrane-cleaving proteases exhibit distinct functions. Here, we review the substrates of these proteases identi ed to date as well as GxGD proteases the current state of knowledge about the physiological implications of these proteolytic events as deduced Signal peptide peptidase from in vivo studies. -
UC Berkeley UC Berkeley Electronic Theses and Dissertations
UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Networks of Splice Factor Regulation by Unproductive Splicing Coupled With NMD Permalink https://escholarship.org/uc/item/4md923q7 Author Desai, Anna Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Networks of Splice Factor Regulation by Unproductive Splicing Coupled With NMD by Anna Maria Desai A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Comparative Biochemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Steven E. Brenner, Chair Professor Donald Rio Professor Lin He Fall 2017 Abstract Networks of Splice Factor Regulation by Unproductive Splicing Coupled With NMD by Anna Maria Desai Doctor of Philosophy in Comparative Biochemistry University of California, Berkeley Professor Steven E. Brenner, Chair Virtually all multi-exon genes undergo alternative splicing (AS) to generate multiple protein isoforms. Alternative splicing is regulated by splicing factors, such as the serine/arginine rich (SR) protein family and the heterogeneous nuclear ribonucleoproteins (hnRNPs). Splicing factors are essential and highly conserved. It has been shown that splicing factors modulate alternative splicing of their own transcripts and of transcripts encoding other splicing factors. However, the extent of this alternative splicing regulation has not yet been determined. I hypothesize that the splicing factor network extends to many SR and hnRNP proteins, and is regulated by alternative splicing coupled to the nonsense mediated mRNA decay (NMD) surveillance pathway. The NMD pathway has a role in preventing accumulation of erroneous transcripts with dominant negative phenotypes. -
Identification of the Long, Edited Dsrnaome of LPS-Stimulated Immune Cells
Downloaded from genome.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Identification of the long, edited dsRNAome of LPS-stimulated immune cells Matthew G. Blango and Brenda L. Bass* Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, USA * Correspondence: [email protected] Phone: 801-581-4884 Running title: dsRNAome of mammalian immune cells Keywords: dsRNA, RNA binding protein, ADAR, Inosine, RNA editing, LPS 1 Downloaded from genome.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Endogenous double-stranded RNA (dsRNA) must be intricately regulated in mammals to prevent aberrant activation of host inflammatory pathways by cytosolic dsRNA binding proteins. Here we define the long, endogenous dsRNA repertoire in mammalian macrophages and monocytes during the inflammatory response to bacterial lipopolysaccharide. Hyperediting by adenosine deaminases that act on RNA (ADAR) enzymes was quantified over time using RNA-seq data from activated mouse macrophages to identify 342 Editing Enriched Regions (EERs), indicative of highly structured dsRNA. Analysis of publicly available datasets for samples of human peripheral blood monocytes resulted in discovery of 3,438 EERs in the human transcriptome. Human EERs had predicted secondary structures that were significantly more stable than those of mouse EERs and were located primarily in introns, whereas nearly all mouse EERs were in 3’UTRs. Seventy-four mouse EER-associated genes contained an EER in the orthologous human gene, although nucleotide sequence and position were only rarely conserved. Among these conserved EER-associated genes were several TNFα-signaling genes, including Sppl2a and Tnfrsf1b, important for processing and recognition of TNFα, respectively. -
Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth
Research Article: New Research Development Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth Jeremy S. Toma,1 Konstantina Karamboulas,1,ª Matthew J. Carr,1,2,ª Adelaida Kolaj,1,3 Scott A. Yuzwa,1 Neemat Mahmud,1,3 Mekayla A. Storer,1 David R. Kaplan,1,2,4 and Freda D. Miller1,2,3,4 https://doi.org/10.1523/ENEURO.0066-20.2020 1Program in Neurosciences and Mental Health, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada, 2Institute of Medical Sciences University of Toronto, Toronto, Ontario M5G 1A8, Canada, 3Department of Physiology, University of Toronto, Toronto, Ontario M5G 1A8, Canada, and 4Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1A8, Canada Abstract Peripheral nerves provide a supportive growth environment for developing and regenerating axons and are es- sential for maintenance and repair of many non-neural tissues. This capacity has largely been ascribed to paracrine factors secreted by nerve-resident Schwann cells. Here, we used single-cell transcriptional profiling to identify ligands made by different injured rodent nerve cell types and have combined this with cell-surface mass spectrometry to computationally model potential paracrine interactions with peripheral neurons. These analyses show that peripheral nerves make many ligands predicted to act on peripheral and CNS neurons, in- cluding known and previously uncharacterized ligands. While Schwann cells are an important ligand source within injured nerves, more than half of the predicted ligands are made by nerve-resident mesenchymal cells, including the endoneurial cells most closely associated with peripheral axons. At least three of these mesen- chymal ligands, ANGPT1, CCL11, and VEGFC, promote growth when locally applied on sympathetic axons. -
Facteur De Risque Génétique Aux Maladies Inflammatoires De L’Intestin Et Modulateur D’Inflammation
Université de Montréal MAST3 : facteur de risque génétique aux maladies inflammatoires de l’intestin et modulateur d’inflammation par Catherine Labbé Département de sciences biomédicales Faculté de médecine Thèse présentée à la Faculté de médecine en vue de l’obtention du grade de doctorat en sciences biomédicales 5 août, 2011 © Catherine Labbé, 2011 Université de Montréal Faculté de médecine Cette thèse intitulée : MAST3 : facteur de risque génétique aux maladies inflammatoires de l’intestin et modulateur d’inflammation Présentée par : Catherine Labbé a été évaluée par un jury composé des personnes suivantes : Daniel Sinnett, président-rapporteur John D. Rioux, directeur de recherche Zoha Kibar, membre du jury Yohan Bossé, examinateur externe Gaëtan Mayer, représentant du doyen de la FES i Résumé La maladie de Crohn (MC) et la colite ulcéreuse (CU) sont des maladies inflammatoires chroniques du tube digestif qu’on regroupe sous le terme maladies inflammatoires de l’intestin (MII). Les mécanismes moléculaires menant au développement des MII ne sont pas entièrement connus, mais des études génétiques et fonctionnelles ont permis de mettre en évidence des interactions entre des prédispositions génétiques et des facteurs environnementaux - notamment la flore intestinale – qui contribuent au développement d’une dérégulation de la réponse immunitaire menant à l’inflammation de la muqueuse intestinale. Des études d’association pangénomiques et ciblées ont permis d’identifier plusieurs gènes de susceptibilité aux MII mais les estimations de la contribution de ces gènes à l’héritabilité suggèrent que plusieurs gènes restent à découvrir. Certains d’entre eux peuvent se trouver dans les régions identifiées par des études de liaison génétique. -
Homo Sapiens, Homo Neanderthalensis and the Denisova Specimen: New Insights on Their Evolutionary Histories Using Whole-Genome Comparisons
Genetics and Molecular Biology, 35, 4 (suppl), 904-911 (2012) Copyright © 2012, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Research Article Homo sapiens, Homo neanderthalensis and the Denisova specimen: New insights on their evolutionary histories using whole-genome comparisons Vanessa Rodrigues Paixão-Côrtes, Lucas Henrique Viscardi, Francisco Mauro Salzano, Tábita Hünemeier and Maria Cátira Bortolini Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Abstract After a brief review of the most recent findings in the study of human evolution, an extensive comparison of the com- plete genomes of our nearest relative, the chimpanzee (Pan troglodytes), of extant Homo sapiens, archaic Homo neanderthalensis and the Denisova specimen were made. The focus was on non-synonymous mutations, which consequently had an impact on protein levels and these changes were classified according to degree of effect. A to- tal of 10,447 non-synonymous substitutions were found in which the derived allele is fixed or nearly fixed in humans as compared to chimpanzee. Their most frequent location was on chromosome 21. Their presence was then searched in the two archaic genomes. Mutations in 381 genes would imply radical amino acid changes, with a frac- tion of these related to olfaction and other important physiological processes. Eight new alleles were identified in the Neanderthal and/or Denisova genetic pools. Four others, possibly affecting cognition, occured both in the sapiens and two other archaic genomes. The selective sweep that gave rise to Homo sapiens could, therefore, have initiated before the modern/archaic human divergence. -
Effects of Inhibitors of FGFR3 on Gene Transcription
(19) TZZ 54¥9A_T (11) EP 2 546 359 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.01.2013 Bulletin 2013/03 C12Q 1/68 (2006.01) (21) Application number: 12163693.0 (22) Date of filing: 07.12.2006 (84) Designated Contracting States: •Moler,Edward AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Emeryville, CA 94662-8097 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Rowe, Michael SK TR Emeryville, CA 94662-8097 (US) • Stewart, Keith (30) Priority: 08.12.2005 US 748944 P Toronto, Ontario M5G 2M9 (CA) • Trudel, Suzanne (62) Document number(s) of the earlier application(s) in Toronto, Ontario M5G 2M9 (CA) accordance with Art. 76 EPC: 06840156.1 / 1 960 547 (74) Representative: UEXKÜLL & STOLBERG Patentanwälte (71) Applicant: Novartis AG Beselerstrasse 4 4056 Basel (CH) 22607 Hamburg (DE) (72) Inventors: Remarks: •Heise,Carla •This application was filed on 11-04-2012 as a Emeryville, CA 94662-8097 (US) divisional application to the application mentioned •Masih-Khan, Esther under INID code 62. Toronto, Ontario M5G 2M9 (CA) •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) Effects of inhibitors of FGFR3 on gene transcription (57) Methods of utilizing biomarkers to identify pa- hibition, are measured and identifications or adjustments tients for treatment or to monitor response to treatment may be made accordingly. are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 in- EP 2 546 359 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 546 359 A1 Description BACKGROUND OF THE INVENTION 5 [0001] The present invention relates generally to the field of pharmacogenomics and in particular to the use of biomar- kers for identifying patients suitable for treatment as well as to methods of following their response to methods of treatment. -
The Glomerular Transcriptome and a Predicted Protein–Protein Interaction Network
BASIC RESEARCH www.jasn.org The Glomerular Transcriptome and a Predicted Protein–Protein Interaction Network Liqun He,* Ying Sun,* Minoru Takemoto,* Jenny Norlin,* Karl Tryggvason,* Tore Samuelsson,† and Christer Betsholtz*‡ *Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, and ‡Department of Medicine, Karolinska Institutet, Stockholm, and †Department of Medical Biochemistry, Go¨teborg University, Go¨teborg, Sweden ABSTRACT To increase our understanding of the molecular composition of the kidney glomerulus, we performed a meta-analysis of available glomerular transcriptional profiles made from mouse and man using five different methodologies. We generated a combined catalogue of glomerulus-enriched genes that emerged from these different sources and then used this to construct a predicted protein–protein interaction network in the glomerulus (GlomNet). The combined glomerulus-enriched gene catalogue provides the most comprehensive picture of the molecular composition of the glomerulus currently available, and GlomNet contributes an integrative systems biology approach to the understanding of glomerular signaling networks that operate during development, function, and disease. J Am Soc Nephrol 19: 260–268, 2008. doi: 10.1681/ASN.2007050588 Many kidney diseases and, importantly, approxi- nins have been shown to be mutated in Alport syn- mately two thirds of all cases of ESRD originate with drome and Pierson congenital nephrotic syndromes, glomerular disease. Most cases of glomerular disease respectively.11,12 Genetic studies in mice have further are caused by systemic disorders (e.g., diabetes, hyper- revealed genes and proteins of importance for glomer- tension, lupus, obesity) for which the molecular ulus development and function, such as podoca- pathogeneses of the glomerular complications are un- lyxin,13 CD2AP,14 NEPH1,15 FAT1,16 forkhead box known. -
The Familial Dementia Gene Revisited: a Missense Mutation Revealed By
Human Molecular Genetics, 2014, Vol. 23, No. 2 491–501 doi:10.1093/hmg/ddt439 Advance Access published on September 10, 2013 The familial dementia gene revisited: a missense mutation revealed by whole-exome sequencing identifies ITM2B as a candidate gene underlying a novel autosomal dominant retinal dystrophy in a large family Isabelle Audo1,2,3,4,5,∗, Kinga Bujakowska1,2,3, Elise Orhan1,2,3, Said El Shamieh1,2,3, Florian Downloaded from https://academic.oup.com/hmg/article/23/2/491/663466 by guest on 01 October 2021 Sennlaub1,2,3, Xavier Guillonneau1,2,3, Aline Antonio1,2,3, Christelle Michiels1,2,3, Marie-Elise Lancelot1,2,3, Melanie Letexier6, Jean-Paul Saraiva6, Hoan Nguyen7, Tien D. Luu7, Thierry Le´veillard1,2,3, Olivier Poch7,He´le`ne Dollfus8,9, Michel Paques1,2,3,4, Olivier Goureau1,2,3, Saddek Mohand-Saı¨d1,2,3,4, Shomi S. Bhattacharya1,2,3,5,10, Jose´-Alain Sahel1,2,3,4,11,12 and Christina Zeitz1,2,3 1INSERM, U968, Paris F-75012, France, 2CNRS, UMR_7210, Paris F-75012, France, 3Department of Genetics, Institut de la Vision, UPMC Univ Paris 06, UMR_S 968, Paris F-75012, France, 4Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, INSERM-DHOS CIC 503, Paris F-75012, France, 5Department of Genetics, UCL-Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK, 6IntegraGen SA, Genopole CAMPUS 1 bat G8, Evry FR- 91030, France, 7Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, Illkirch Cedex 67404, France, 8Centre de Re´fe´rence pour les Affections Rares en Ge´ne´tique Ophtalmologique, Hoˆpitaux -
A Genetic Profile of Refractory Individuals with Major Depressive Disorder and Their Responsiveness to Transcranial Magnetic Stimulation
medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20063404; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . A Genetic Profile of Refractory Individuals with Major Depressive Disorder and Their Responsiveness to Transcranial Magnetic Stimulation Nathália G. Souza-Silva a, Eduardo S. Nicolau a, Kate Hoy b, Ziarih Hawi c, Mark A. Bellgrove c, Débora M. Miranda a,d, Marco A. Romano-Silva a,e, Paul B. Fitzgerald b,f a Centro de Tecnologia em Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil b Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School, Commercial Rd, Melbourne, Victoria, Australia c School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia d Departamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil e Departamento de Saúde Mental, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil f Epworth Healthcare, The Epworth Clinic, Camberwell, Victoria, Australia, 3004 To whom correspondence may be addressed: Prof. Marco A. Romano-Silva Avenida Professor Alfredo Balena, 190, sala 114. Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil (e-mail to: romano- [email protected]) ABSTRACT Background: Major depressive disorder (MDD) is a debilitating illness characterized by the persistence of negative thoughts and emotions. Although antidepressant medications are effective, less than half of patients achieve complete remission despite multiple treatment trials. -
Sirna Screen Identifies QPCT As a Druggable Target For
siRNA screen identifies QPCT as a druggable target for Huntington’s disease Maria Jimenez-Sanchez1, Wun Lam1,2, Michael Hannus3,§, Birte Sönnichsen3,§, Sara Imarisio1,2,§, Angeleen Fleming1,4,§, Alessia Tarditi6,#, Fiona Menzies1, Teresa Ed Dami1,4,5, Catherine Xu1,4, Eduardo Gonzalez-Couto6,€, Giulia Lazzeroni6, Freddy Heitz6,£, Daniela Diamanti6, Luisa Massai6, Venkata P. Satagopam7,8, Guido Marconi6,$, Chiara Caramelli6,&, Arianna Nencini6, Matteo Andreini6, Gian Luca Sardone6, Nicola P. Caradonna6, Valentina Porcari6, Carla Scali6, Reinhard Schneider7,8, Giuseppe Pollio6, Cahir J. O’Kane2, Andrea Caricasole6,^,* and David C. Rubinsztein1,* 1Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK 2 Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK 3Cenix BioScience GmbH, Tatzberg 47, 01307 Dresden, Germany 4Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, UK, CB2 3EG. 5 Department of Neuroscience, Psychology, Drug Research and Child Health, Division of Pharmacology and Toxicology, University of Florence, Florence, Italy 6Siena Biotech. Strada del Petriccio e Belriguardo, 35 53100 Siena, Italy 7Structural and Computational Biology, EMBL, Meyerhofstr.1, 69117, Heidelberg, Germany 8Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Campus Belval, House of Biomedicine, 7 avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg -
Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets
bioRxiv preprint doi: https://doi.org/10.1101/2021.08.04.455031; this version posted August 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Canine oral melanoma genomic and transcriptomic study defines two molecular subgroups with different therapeutical targets Anais Prouteau1, Stephanie Mottier1, Aline Primot1, Edouard Cadieu1, Laura Bachelot1, Nadine Botherel1, Florian Cabillic2, Armel Houel1, Laurence Cornevin2, Camille Kergal1, Sebastien Corre1, Jerome Abadie3, Christophe Hitte1, David Gilot1, Kerstin Lindblad-Toh4,5, Catherine Andre1, Thomas Derrien1* and Benoit Hedan1* 1 University of Rennes, CNRS, IGDR—UMR 6290, F-35000 Rennes, France, 2 Laboratoire de cytogénétique et biologie cellulaire, CHU de Rennes, INSERM, INRA, Univ. Rennes 1, Nutrition Metabolisms and Cancer, 35043 Rennes, France, 3 Laboniris, Department of Biology, Pathology and Food Sciences, Oniris, Nantes, France, 4 Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, 5 Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Box582, SE-751 24 Uppsala, Sweden, * T.D. and B.H should be considered co-corresponding authors Email address: thomas.derrien@univ rennes1.fr (T. Derrien), [email protected] (B. Hedan) *Corresponding author Abstract: Mucosal melanoma (MM) is a rare and aggressive clinical cancer that occurs mostly in the head, neck, and anogenital regions. Despite recent advances in genetics and the development of revolutionary treatments, such as immunotherapy, the prognosis for MM remains poor. Canine MM shares several clinical, histological, and genetic features with its human counterpart, offering a relevant spontaneous and immunocompetent model to decipher the genetic bases and explore treatment options for human MM.